Source: Hemostemix Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units
  • Each unit consists of one common share and one share purchase warrant
  • Proceeds from the offering will be used to pay current filing and regulatory fees, reduce debt, and begin production of ACP-01
  • Hemostemix is an autologous stem cell therapy company
  • Shares of Hemostemix Inc. (HEM) opened trading at C$0.35

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.

Each unit consists of one common share and one share purchase warrant.  Each warrant will entitle the holder to acquire one additional common share for $0.55 for 24 months.

Warrants are subject to an acceleration clause.

Proceeds from the offering will be used to pay current filing and regulatory fees, reduce debt and begin production of ACP-01.

All securities issued will be subject to a four-month hold period.

Hemostemix is an autologous stem cell therapy company. The company has developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.

Shares of Hemostemix Inc. (HEM) opened trading at C$0.35.

More From The Market Herald

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

" Feeding our plant-based future

One of the fastest-growing segments today is the plant-based industry, as the push towards cleaner lifestyles, eating habits, and sustainable living choices fuel

" Salona Global (TSXV:SGMD) expands product distribution

Salona Global (SGMD) has signed an agreement to distribute the Hyperice suite of products and delivered 600 units of its newly launched Mio-Guard.